Founded in 2009, PolyPhotonix is a bio-photonic research company developing light therapy treatments for macular eye disease as well as other medical conditions.
In just six years PolyPhotonix has grown from one employee with an idea, to manufacturing a phototherapy eye mask that independent health economists working with the NHS estimate could save on adoption of the technology in excess of £1 billion a year. PolyPhotonix have developed a treatment for one of the most common causes of blindness in the western world, Diabetic Retinopathy. The Noctura 400® treatment is provided at a fraction of current treatments costs and creates the opportunity to provide affordable treatment to the millions who are affected across the globe.
Right hand image – Courtesy of BQ Magazine and KG Photography.
With over 15 years’ experience in the field of medical research and printed electronics, Richard Kirk the CEO is a well recognized as a pioneer in material science and its applications.
He is credited for many world’s first applications using inorganic and organic light emitting materials. He is a regular keynote speaker internationally and sits on a number of industrial and government advisory boards. Richard and his company have won many international and national awards for innovation, research and business.
With an early life as a successful artist in based in France, Richard has a thorough understanding of the creative process and a unique view on the development of markets for innovative research.